Cell and Gene Therapy Deals Analysis, 2021-2024

Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024 is published in two installments, the first in Q2 2024 and the second in Q4 2024. Customers who purchase the report will receive both installments.

The Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024 offers a comprehensive look at the dynamic and rapidly evolving cell and gene therapy market. This report highlights the significant deal-making activities that have taken place from Q1 2021 to Q1 2024, providing valuable insights for companies and stakeholders looking to understand and leverage the trends shaping this burgeoning field.

No report published by a major market research publisher has tackled the cell and gene therapy dealmaking space more comprehensively. With cell and gene therapy is becoming a highly competitive marketplace, over a thousand companies are specifically referenced in this report.

Why This Report?

With over 1,500 companies actively involved in the cell and gene therapy space, understanding the trends and competitive landscape is crucial for strategic planning. Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024 provides the essential market analysis needed to navigate and capitalize on the opportunities within this fast-growing industry.

Report Highlights:

Quarterly Funding Trends (Q1 2021-Q1 2024): Graphical representation of funding amounts, showcasing investment influx in cell and gene therapy.
Deal Types: Comprehensive categorization of 2000+ deals, including venture capital, private investments, mergers, acquisitions, strategic collaborations, licensing, manufacturing/ supply, and distribution/ co-marketing.
Top Deal-Makers: Identification of the most active companies by deal type and overall deal activity.
Regional Deal Breakdown: Percentage analysis of deal-making activities across different regions.

Who Should Buy This Report

Understanding the volumes of deals that have been made, who is making which type and how many, and the deals' details, is critical to finding how to take advantage of the opportunities in one of the fastest-growing markets.

Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024 is designed to provide companies entering or already in this market with knowledge of the trends in deals that will shape future growth and competition.

The following is just some of the information in this report:

Quarterly Funding Amounts Q1 2021- Q1 2024 by Type and Region
Specific details of 2000+ CGT Deals
Venture Capital/Private Funding Round Amounts, By Quarter
Chronological Trends Presented in Multiple Categories (VC, M&A, Other Areas)
Deals by Type - Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation
Most Active Deal-Making Companies, by Type of Deal (Acquisition/Merger/ Strategic Investment, Overall Deals, Collaborations)
Regional Breakdown of Dealmaking [North America, Europe, APAC, Rest of World] (%)

Methodology

The report’s insights are derived from a blend of primary and secondary research, including interviews with industry professionals, comprehensive literature reviews, and analysis of company and government reports.

Chapter 1: Executive Summary

Introduction
$35 Billion in Investment in 2023
Figure 1-1: Total Deals Per Month, April 2021-April 2024 (Count)
Figure 1-2: Total Deals Per Month, by Type [Vc/ Private, Ipo/Fpo/Spac; and All Other Deals], April 2021-April 2024 (Count)
Quarterly Funding Amounts
Table 1-1: Total Quarterly Funding and Shares, by Type [M&A; Venture Capital/Private; Ipo/Fpo; Collab; Spac; and Strat Inv], Q1 2024 (In Millions $)
Table 1-2: Total Quarterly Funding and Shares, by Type [M&A; Venture Capital/Private; Ipo/Fpo; Collab; Spac; and Strat Inv], 2023 (In Millions $)
Table 1-3: Total Quarterly Funding and Shares, by Type [M&A; Venture Capital/Private; Ipo/Fpo; Collab; Spac; and Strat Inv], 2022 (In Millions $)
Table 1-4: Total Quarterly Funding and Shares, by Type [M&A; Venture Capital/Private; Ipo/Fpo; Collab; Spac; and Strat Inv], 2021 (In Millions $)
Table 1-5: Total Quarterly Funding, by Type [M&A; Venture Capital/Private; Ipo/Fpo; Collab; Spac; and Strat Inv], 2021-Q1 2024 (In Millions $)
Figure 1-3: Total Quarterly Funding, Q1 2021- Q1 2024 (In Millions $)
Figure 1-4: Total Quarterly Funding, by Type [M&A; Venture Capital/Private; Ipo/Fpo; Collab; Spac; and Strat Inv], Q1 2021-Q1 2024 (In Millions $)
Quarterly Funding Category Shares, Q1 2021 Through Q1 2024
Table 1-6: Total Quarterly Funding Share, by Type [M&A; Venture Capital/Private; Ipo/Fpo; Collab; Spac; and Strat Inv], 2023 (%)
Table 1-7: Total Quarterly Funding Share, by Type [M&A; Venture Capital/Private; Ipo/Fpo; Collab; Spac; and Strat Inv], 2022
Table 1-8: Total Quarterly Funding Share, by Type [M&A; Venture Capital/Private; Ipo/Fpo; Collab; Spac; and Strat Inv], 2021 (%)
Table 1-9: Total Quarterly Funding Share, by Type [M&A; Venture Capital/Private; Ipo/Fpo; Collab; Spac; and Strat Inv], 2021-Q1 2024 (%)
Figure 1-5: Total Quarterly Funding Share, by Type [M&A; Venture Capital/Private; Ipo/Fpo; Collab; Spac; and Strat Inv], Q1 2021-Q1 2024 (%)
Figure 1-6: January-April 2024 Funding Share, by Type of Funding [M&A; Venture Capital/Private; Ipo/Fpo; Collab; Spac; and Strat Inv] (%)
Figure 1-7: 2023 Funding Share, by Type of Funding [M&A; Venture Capital/Private; Ipo/Fpo; Collab; Spac; and Strat Inv] (%)
Figure 1-8: 2022 Funding Share, by Type of Funding [M&A; Venture Capital/Private; Ipo/Fpo; Collab; Spac; and Strat Inv] (%)
Figure 1-9: 2021 Funding Share, by Type of Funding [M&A; Venture Capital/Private; Ipo/Fpo; Collab; Spac; and Strat Inv] (%)
Quarterly Deal Counts by Category, Q1 2021 - Q1 2024
Table 1-10: Quarterly Count of Deals, Q1 2024, by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/Spac; Manufacturing, Supply Chain; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal] (Total Number) (%)
Table 1-11: Quarterly Count of Deals, by 2023 Quarter, by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/Spac; Manufacturing, Supply Chain; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal] (Total Number) (%)
Table 1-12: Quarterly Count of Deals, by 2022 Quarter, by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/Spac; Manufacturing, Supply Chain; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture] (Total Number) (%)
Table 1-13: Quarterly Count of Deals, by 2021 Quarter, by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/Spac; Manufacturing, Supply Chain; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture] (Total Number) (%)
Table 1-14: Yearly Shares of Number of Deals, by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/Spac; Manufacturing, Supply Chain; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture], 2021-2024 Partial (%)
Growth in Collaborations, Manufacturing/Supply Chain Deals, Licensing, Distribution/ Co-Marketing Highlight Activity in Cell and Gene Therapy
Figure 1-10A: Yearly Shares of Number of Deals, by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/Spac; Manufacturing, Supply Chain], 2021-2024 Partial (%)
Figure 1-10B: Yearly Shares of Number of Deals, by Category [Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture], 2021-2024 Partial (%)
Figure 1-11: Most Frequent Types of Deals, by Quarter, by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/Spac; and Manufacturing, Supply Chain], Q1 2021-Q1 2024 (Total Number)
A Look at Less Frequent Cgt Deal Types
Figure 1-12: Lower Frequency Deal Types, by Quarter, by Category [Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture], Q1 2021-Q1 2024 (Total Number)
Figure 1-13: Merger/Acquisition Amount, by Quarter, Q1 2021-Q1 2024 (In Millions $)
Figure 1-14: Venture Capital/Private Funding Round Amount, by Quarter, Q1 2021-Q1 2024 (In Millions $)
Figure 1-15: Ipo/Fpo Amount, by Quarter, Q1 2021-Q1 2024 (In Millions $)
Figure 1-16: Spac Portion Amount, by Year, 2021-2023 (In Millions $)
Most Active Companies
Table 1-15: Most Active Companies in Cgt Deals, Collaborations, Overall 2021-April 2024
Figure 1-17: Most Active Companies in Cgt Deals, Collaborations, Overall 2021-April 2024

Chapter 2: Venture Capital & Private Funding

Vc/Private Funding in Flux
Figure 2-1: Total Number of Private Funding/Vc Rounds, by Month, Jan 2021-April 2024 (Count)
Figure 2-2: Average Private Funding/Vc Round Amount, by Quarter, Q1 2021-Q1 2024 (In Millions $)
Table 2-1: Regional Venture Capital/Private Funding, by Region [North America, Europe, Apac, Rest of World], by Quarter Q1 2021-Q1 2024 (In Millions $) (%)
Figure 2-3: Quarterly Venture Capital/Private Total Funding, by Region [North America, Europe, Apac, Rest of World], Q1 2021-Q1 2024 (In Millions $)
Table 2-2: Regional Venture Capital/Private Funding Shares, by Region [North America, Europe, Apac, Rest of World], by Quarter Q1 2021-Q1 2024 (%)
Figure 2-4: Regional Venture Capital/Private Funding Shares, by Region [North America, Europe, Apac, Rest of World], by Quarter, Q1 2021-Q1 2024, (%)
Figure 2-5: Venture Capital/Private Funding Round Amounts, by Quarter, Q1 2021-Q1 2024 (In Millions $)
Figure 2-6: Scaled Venture Capital/Private Funding Round Amounts, by Quarter, Q1 2021-Q1 2024 (In Millions $)
Table 2-3: Venture Capital/Private Fundraising Deals, Q1 2024
Table 2-4: Venture Capital/Private Fundraising Deals, Q4 2023
Table 2-5: Venture Capital/Private Fundraising Deals, Q3 2023
Table 2-6: Venture Capital/Private Fundraising Deals, Q2 2023
Table 2-7: Venture Capital/Private, Q1 2023
Table 2-8: Venture Capital/Private Fundraising Deals, Q4 2022
Table 2-9: Venture Capital/Private Fundraising Deals, Q3 2022
Table 2-10: Venture Capital/Private, Q2 2022
Table 2-11: Venture Capital/Private, Q1 2022

Chapter 3: Strategic Investments

Strategic Investments in Cell and Gene Therapy
Figure 3-1: Total Number of Strategic Investments, by Quarter, Q1 2021-Q1 2024 (Count)
Figure 3-2: Average Strategic Investment Amount, by Quarter, Q1 2021-Q1 2024 (In Millions $)
Figure 3-3: Total Strategic Investment Amount, by Quarter, Q1 2021-Q1 2024 (In Millions $)
Table 3-1: Strategic Investment Total Amounts, Counts, and Averages, by Quarter, Q1 2021-Q1 2024, (In Millions $)
Table 3-2: Strategic Investments, January 2021-April 2024
Table 3-3: Most Active in Acquisition/Merger/Strategic Investment, 2021-April 2024
Figure 3-4: Most Active in Acquisition/Merger/Strategic Investment, 2021-April 2024

Chapter 4: Ipos, Fpos, & Spacs

North America Sees the Majority of Proceeds from Ipos, Fpos, Spacs
Figure 4-1: Total Number of Ipos/ Fpos, by Month, January 2021-April 2024 (Count)
Figure 4-2: Average Ipo/ Fpo Proceeds, by Quarter, Q1 2021-Q1 2024 (In Millions $)
Table 4-1: Quarterly Ipo/ Fpo Total Funding, by Region [North America, Europe, Apac], Q1 2021-Q1 2024 (In Millions $)
Figure 4-3: Total Ipo/Fpo Funding, by Quarter, by Region [North America, Europe, Apac], Q1 2021-Q1 2024 (In Millions $)
Table 4-2: Regional Ipo/Fpo Funding Shares, by Quarter [North America, Europe, Apac], Q1 2021-Q1 2024 (%)
Figure 4-4: Regional Ipo/Fpo Funding Shares, by Quarter, Q1 2021-Q1 2024 [North America, Apac, and Europe) (%)
Figure 4-5: Ipo/Fpo Amounts, by Quarter, Q1 2021-Q1 2024 (In Millions $)
Table 4-3: Quarterly Spac Funding Portion, Q1 2021-Q1 2024 (In Millions $)
Figure 4-6: Quarterly Spac Funding Portion Total and Average, Q1 2021-Q1 2024 (In Millions $)
Table 4-4: Ipo/Fpo Deals, January -May 2024 (In Millions $)
Table 4-5: Ipo/Fpo Deals, Q4 2023 (In Millions $)
Table 4-6: Ipo/Fpo Deals, Q3 2023 (In Millions $)
Table 4-7: Ipo/Fpo Deals, Q2 2023 (In Millions $)
Table 4-8: Ipo/Fpo Deals, Q1 2023 (In Millions $)
Table 4-9: Ipo/Fpo Deals, Q4 2022 (In Millions $)
Table 4-10: Ipo/Fpo Deals, Q3 2022 (In Millions $)
Table 4-11: Ipo/Fpo Deals, Q2 2022 (In Millions $)
Table 4-12: Ipo/Fpo Deals, Q1 2022 (In Millions $)
Table 4-13: Spac Portion, Q1 2021-Q1 2024 (In Millions $)
Figure 4-7: Spac Portion Amount, by Year, 2021-2023 (In Millions $)

Chapter 5: Mergers & Acquisitions (M&A)

Growing Numbers of M&A, Despite Lower Average Value
Figure 5-1: Total Number of Mergers and Acquisitions, by Month, January 2021-April 2024 (Count)
Figure 5-2: Average Merger/Acquisition Amount, by Quarter, Q1 2021-Q1 2024 (In Millions $)
Table 5-1: Quarterly Merger and Acquisition Values, Counts, and Averages, Q1 2021-Q1 2024 (In Millions $) (Total Count)
Figure 5-3: Merger/ Acquisition Transactions Global Total, by Quarter [Q1 2022- Q1 2024] (In Millions $)
Figure 5-4: Merger/Acquisition Amounts, by Quarter, Q1 2021-Q1 2024 (In Millions $)
Table 5-2: Mergers and Acquisitions Announcements, January-May 2024 (In Millions $)
Table 5-3: Mergers and Acquisitions Announcements, Q4 2023 (In Millions $)
Table 5-4: Mergers and Acquisitions Announcements, Q3 2023 (In Millions $)
Table 5-5: Mergers and Acquisitions Announcements, Q2 2023 (In Millions $)
Table 5-6: Mergers and Acquisitions Announcements, Q1 2023 (In Millions $)
Table 5-7: Mergers and Acquisitions, Q4 2022 (In Millions $)
Table 5-8: Mergers and Acquisitions, Q3 2022 (In Millions $)
Table 5-9: Mergers and Acquisitions, Q2 2022 (In Millions $)
Table 5-10: Mergers and Acquisitions, Q1 2022 (In Millions $)
Table 5-11: Most Active in Acquisition/Merger/ Strategic Investment, 2021-April 2024 (Count)
Figure 5-5: Most Active in Acquisition/Merger/Strategic Investment, 2021-April 2024

Chapter 6: Technology/Research/Strategic Collaborations

Cgt Market Sees a Broad Variety of Collaborations
Figure 6-1: Total Number of Tech/Research/Strategic Collaborations, by Month, January 2021-April 2024 (Count)
Figure 6-2: Total Number of Collaborations with Upfront And/Or Milestone Payments, by Quarter, Q1 2021-Q1 2024 (In Millions $)
Table 6-1: Collaboration Upfront and Future/Milestone Payments, Counts, Averages, Q1 2021-Q1 2024 (In Millions $) (Count)
Figure 6-3: Average Collaboration Upfront Payment, by Quarter, Q2 2021-Q1 2024 (In Millions $)
Figure 6-4: Research Collaboration Upfront Payments Total, by Quarter, Q2 2021-Q1 2024 (In Millions $)
Figure 6-5: Average Collaboration Future/Milestone Payments, by Quarter, Q2 2021-Q1 2024 (In Millions $)
Figure 6-6: Total Collaboration Future/ Milestone Payments, by Quarter, Q2 2021-Q1 2024 (In Millions $)
Table 6-2: Technology/Research/Strategic Collaboration Deals, January-May 2024
Table 6-3: Technology/Research/Strategic Collaboration Deals, Q4 2023
Table 6-4: Technology/Research/Strategic Collaboration Deals, Q3 2023
Table 6-5: Technology/Research/Strategic Collaboration Deals, Q2 2023
Table 6-6: Technology/Research/Strategic Collaboration Deals, Q1 2022-Q1 2023
Table 6-7: Most Active in Research/Strategic Collaborations, 2021-April 2024 (Count)
Figure 6-7: Most Active in Research/ Strategic Collaborations, 2021-April 2024 (Count)

Chapter 7: Licensing

Stable Levels of Licensing in the Cell and Gene Therapy Market
Figure 7-1: Total Number of Licensing Deals, by Month, January 2021-April 2024 (Count)
Table 7-1: Licensing Deals, January-April 2024
Table 7-2: Licensing Deals, Q4 2023
Table 7-3: Licensing Deals, Q3 2023
Table 7-4: Licensing Deals, Q2 2023
Table 7-5: Licensing Deals, Q1 2022-Q1 2023
Table 7-6: Most Active Companies in Licensing Deals, 2021-April 2024 (Count)
Figure 7-2: Most Active Companies in Licensing Deals, 2021-April 2024 (Count)

Chapter 8: Manufacturing and Supply Chain

Major Growth in Manufacturing and Supply Chain Management Activity in Cgt
Figure 8-1: Total Number of Supply/Manufacturing Deals, by Month, January 2021-April 2024 (Count)
Table 8-1: Manufacturing and Supply Chain Deals, January-May 2024
Table 8-2: Manufacturing and Supply Chain Deals, Q4 2023
Table 8-3: Manufacturing and Supply Chain Deals, Q3 2023
Table 8-4: Manufacturing and Supply Chain Deals, Q2 2023
Table 8-5: Manufacturing and Supply Chain Deals, Q1 2022-Q1 2023
Table 8-6: Most Active Companies in Manufacturing/Supply Deals, 2021-April 2024 (Count)
Figure 8-2: Most Active Companies in Manufacturing/Supply Deals, 2021-April 2024 (Count)

Chapter 9: Distribution & Co-Marketing

A Look at Cgt Distribution and Co-Marketing Deals
Figure 9-1: Total Number of Distribution/ Co-Marketing Deals, by Month, January 2021-April 2024 (Count)
Table 9-1: Distribution & Co-Marketing Deals, January-May 2024
Table 9-2: Distribution & Co-Marketing Deals, Q4 2023
Table 9-3: Distribution & Co-Marketing Deals, Q3 2023
Table 9-4: Distribution & Co-Marketing Deals, Q2 2023
Table 9-5: Distribution & Co-Marketing Deals, Q1 2022-Q1 2024
Table 9-6: Most Active Companies in Manufacturing/ Supply Deals, 2021-April 2024 (Count)
Figure 9-2: Most Active Companies in Manufacturing/ Supply Deals, 2021-April 2024 (Count)

Chapter 10: Other - Jv, Restructuring, Termination, Spinoffs

A Look at Other Types of Deals Impacting Cell and Gene Therapy
Figure 10-1: Total Number of Jv, Restructuring, Termination, by Month [January 2021-April 2024 ] (Total Count)
Table 10-1: Restructuring, Jv, Termination, Spinoffs, January 2022-April 2024

License	Format	Properties	Price
SINGLE USER LICENSE Online Access (PDF)	The product can be accessed through a secure website. Username and password will be sent via email. The format is PDF.	This is a single user license, allowing one user access to the product.	€6159EUR$6,300USD£5,144GBP
1 - 10 USER LICENSE PDF	The product is a PDF.	This is a 1-10 user license, allowing up to ten users have access to the product.	€9238EUR$9,450USD£7,717GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€12318EUR$12,600USD£10,289GBP

Why This Report?

Report Highlights:

Who Should Buy This Report

The following is just some of the information in this report:

Methodology

Table of Contents

Related Topics

Related Reports

Cell Therapy and Gene Therapy Markets (Markets by Disease Type), 2023-2029

Cell and Gene Therapy Manufacturing Market Report: Trends, Forecast and Competitive Analysis to 2030

Global Cell and Gene Therapy Market

Cell and Gene Therapy CRO Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Cell Therapy, Type of Genetic Modification, Stage of Development, Therapeutic Area, End-users and Key Geographical Regions

Cell and Gene Therapy Supply Chain Software Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Process Component, Type of Software, Mode of Deployment, Scale of Operation, Type of End-user and Key Geographical Regions